RxDoctor Payments Data

Agnieszka Kwapniewski, MD

Internal Medicine · North Arlington, NJNPI 1528007457

Payments from drug & device makers

$10,722in general payments, 2019–2025

Across 562 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Boehringer Ingelheim$993
  • Amgen$798
  • Novo Nordisk$778
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$10,675100%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,722 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$57,757
Medicare patients
142
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide63$72,410
OzempicSemaglutide52$66,227
JardianceEmpagliflozin61$65,530
FarxigaDapagliflozin Propanediol58$54,231
EliquisApixaban28$26,980
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,880
JanumetSitagliptin Phos/Metformin Hcl14$12,551
Rosuvastatin Calcium144$3,779
SynthroidLevothyroxine Sodium25$2,675
Atorvastatin Calcium168$2,149
Metoprolol Succinate118$1,883
Levothyroxine Sodium124$1,419
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide48$969
Celecoxib16$907
Valsartan20$900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,321$72,41063 claims
Novo NordiskOzempic$778$66,22752 claims
Boehringer IngelheimJardiance$993$65,53061 claims
AstraZenecaFarxiga$1,725$54,23158 claims
PfizerEliquis$364$26,98028 claims
GSKTrelegy Ellipta$271$12,88012 claims
MerckJanumet$398$12,55114 claims
AbbVieSynthroid$1,201$2,67525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in North Arlington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →